SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-032690
Filing Date
2021-12-29
Accepted
2021-12-29 16:05:15
Documents
14
Period of Report
2021-12-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45497
2 ex99-1.htm EX-99.1 574744
3 ex99-2.htm EX-99.2 159081
  Complete submission text file 0001493152-21-032690.txt   1093428

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rspi-20211223.xsd EX-101.SCH 3036
5 XBRL LABEL FILE rspi-20211223_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE rspi-20211223_pre.xml EX-101.PRE 22597
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3305
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 211528881
SIC: 2834 Pharmaceutical Preparations